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Untargeted metabolic proﬁling has generated large activity in the ﬁeld of clinical biomarker discovery.
Yet, no clinically approved metabolite biomarkers have emerged with failure in validation phases often
being a reason. To investigate why, we have applied untargeted metabolic proﬁling in a retrospective
cohort of serum samples representing non-related diseases. Age and gender matched samples from
patients diagnosed with pneumonia, congestive heart failure, lymphoma and healthy controls were
subject to comprehensive metabolic proﬁling using ultra-performance liquid chromatography-mass
spectrometry (UPLC-MS). The metabolic proﬁle of each diagnosis was compared to the healthy control
group and signiﬁcant metabolites were ﬁltered out using t-test with FDR correction. Metabolites found to
be signiﬁcant between each disease and healthy controls were compared and analyzed for overlap.
Results show that despite differences in etiology and clinical disease presentation, the fraction of me-
tabolites with an overlap between two or more diseases was 61%. A majority of these metabolites can be
associated with immune responses thus representing non-disease speciﬁc events. We show that
metabolic serum proﬁles from patients representing non-related diseases display very similar metabolic
differences when compared to healthy controls. Many of the metabolites discovered as disease speciﬁc in
this study have further been associated with other diseases in the literature. Based on our ﬁndings we
suggest non-related disease controls in metabolomics biomarker discovery studies to increase the
chances of a successful validation and future clinical applications.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Metabolic proﬁling has become an active ﬁeld of clinical
research in several areas of diagnostic medicine [1], but has so far
failed to produce clinically approved novel small molecular bio-
markers. Yet, it is evident from neonatal screening programs with
up to 55 inborn errors of metabolism on the list of screenable
diseases [2], that a disease can be very tightly linked to a metabolic
signature. Likewise, it is a well-established fact that diseases like
cancer have a dramatically altered metabolism to that of normal
proliferating cells [3], providing a biochemical rationale for
biomarker discovery efforts. So why are no novel disease metabo-
lite biomarkers emerging?Biology, Umeå University, SE-
rdstr€om).
r Inc. This is an open access articlA major difference between most inborn errors of metabolism
and a disease like cancer or cardiovascular disease is that while the
ﬁrst most often consist of a point mutation resulting in a single
malfunctioning protein, the latter is a multifactorial disease
developed over longer periods of time often involving several er-
rors occurring in a sequential fashion [3]. Further, the patient being
screened for inborn errors of metabolism is most often only a few
days old, has no established microbiota and rarely has any co-
morbidities whereas the prospective patient being screened for
cancer typically is in the age of 40e70, has a complex microbiota
and is very likely to have some kind of co-morbidity even if undi-
agnosed, increasing the risk of identifying non-speciﬁc biomarkers.
Conceptually the biomarker process can be divided into a dis-
covery- and a clinical validation phase. The discovery phase should
include conﬁrmation of ﬁndings in an external test set and a disease
mechanism hypothesis in order to minimize the risk of costly val-
idations of unspeciﬁc markers [4,5]. So far, no novel metabolite
biomarkers have passed an independent clinical validation phasee under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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cosine was associated with prostate cancer progression both in
urine and tissue [6]. However subsequent studies using comparable
patient samples failed to validate this association [7,8].
In the present study, we have performed metabolic proﬁling,
using LC-MS, of serum from patients representing three completely
unrelated diseases with respect to clinical disease presentation and
etiology; non-Hodgkin lymphoma, community acquired pneu-
monia and congestive heart failure. Resulting proﬁles were
compared separately to healthy controls. Our results indicate that
the number of disease speciﬁc serum metabolites is surprisingly
small. We propose a strategy for clinical discovery projects to in-
crease chances of ﬁnding disease speciﬁc metabolic serum
biomarkers.
2. Materials and methods
2.1. Clinical samples
Serum samples were acquired from the commercial vendor
BioServe and had been collected in accordancewith the Declaration
of Helsinki [9]. Healthy controls (n ¼ 40) and the following three
diseases were included: Congestive heart failure (n ¼ 40), lym-
phoma (n ¼ 40) and community acquired pneumonia (n ¼ 25).
Samples were selected to match for gender and age between
groups. Lymphoma samples were non-Hodgkin lymphomas stage
IeIV. Congestive heart failure samples were stage IIIeIV (Table 1).
Samples were collected at different hospitals according to a stan-
dardized protocol [10] following FDA guidelines and then stored at
a central location. All samples were extracted and prepared at the
same time and analyzed, in a randomized order, over a period of
three days on the same instrument.
2.2. Serum sample preparation
Samples were stored at 80 C. Prior to metabolite extraction,
samples were thawed on ice. 50 mL serum per sample was mixed
with 150 mL MeOH and then centrifuged at 15800g for 15 min. The
supernatant was transferred to a new vial, dried down in a speed
vacuum concentrator and stored at 80 C. Prior to analysis, sam-
ples were re-dissolved in 50 mL 1:1 MeOH:H2O. An aliquot of each
sample was pooled for quality control (QC) samples.
2.3. UPLC-MS analysis
Metabolites were separated by reversed phase liquid chroma-
tography and detected by electrospray ionization mass spectrom-
etry operated in positive and negativemode. The platform usedwas
an Agilent 1290 UPLC-system connected online to an Agilent 6550
Q-ToF mass spectrometer equipped with a JetStream source. 5 mL
per sample of the re-dissolved supernatant were injected onto a
C18 column (Kinetex 100  2.1 mm 2.6 um 100 Å, Phenomenex)Table 1
Clinical samples.
Characteristic Healthy controls (C) Congestive heart
n 40 40
Age, yearsa 52 (41e59) 54 (44e60)
Male/female ratio 20/20 20/20
Disease stage (n) I N/A e
II e
III 32
IV 8
a Data is presented as median (range).using the following mobile phases: H2O with 0.1% formic acid (A)
and 3:1 acetonitrile:isopropanol with 0.1% formic acid (B). All sol-
vents were of HPLC grade and the water was Milli-Q. The following
gradient was used at a ﬂow rate of 0.5 ml/min: Min 0, 5% B; min 8,
95% B; min 10, 95% B; min 10.2, 5% B; min 12, 5% B. MS data was
collected between m/z 70e1700 with the following electrospray
ionization settings: Gas temperature 300 C; gas ﬂow 8 L/min;
nebulizer pressure 40 psi; sheet gas temperature 350 C; sheet gas
ﬂow 11; Vcap 4000; fragmentor 100; skimmer1 45; Octapo-
leRFPeak 750.
Samples were run in randomized order with a QC-sample in-
jection interspersed between every 5 samples. The QC-injections
were used i) to calculate the repeatability of the analytical
method and ii) to evaluate the effect of sample normalization.
Additional QC-sample injections were also made to acquire data
dependent MS/MS spectra for metabolite identiﬁcation purposes.
Blank samples were injected throughout the sample series to
monitor carry over.2.4. Raw data preprocessing
Raw data was processed using the “Find by Molecular Feature”-
function in the software MassHunter Qual version B.06.00 (Agilent)
for peak detection and removal of isotopes and adducts. Generated
CEF ﬁles were then imported into the software Mass Proﬁler Pro-
fessional version B.12.05 (Agilent) for normalization, alignment,
peak ﬁltering and statistical analysis. Samples were normalized to
have equal median intensity. The normalization was based on the
assumption that all serum samples have a similar metabolic proﬁle.
The intention of a sample-wise signal correction method like me-
dian normalization is hence to correct for technical variation in e.g.
sample preparation and MS signal intensity [11]. A two-step
ﬁltering approach was used for peak quality control: ﬁrstly, only
peaks present in at least 75% of samples in at least one group were
retained; secondly, only peaks above a speciﬁed intensity level in
the raw data were used for further analysis.2.5. Univariate statistical analysis
To identify single metabolite markers discriminating disease
from healthy controls, univariate statistical analysis was applied.
For each disease, Student's t-test with Benjamini Hochberg FDR
correction for multiple testing was performed. Missing values were
excluded and the comparison of pneumonia with healthy controls
was done by t-test not assuming equal variances due to differences
in sample size.
Metabolite features with FDR <0.05 were examined in the raw
data using the “Find by Formula”-function in MassHunter Qual in
combination with manual curation. Low quality features such as
PEG contaminations and erroneous peak detection were removed
from the data set. In the case of poor automatic peak area inte-
gration, features were re-integrated manually. The signiﬁcance offailure (H) Community acquired pneumonia (P) Lymphoma (L)
25 40
54 (41e60) 51 (41e60)
12/13 20/20
N/A 8
14
9
9
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t-test using the software Prism version 6.07 (GraphPad). Prismwas
further used to perform Pearson correlation analyses and to create
box plots. Overlap analysis of metabolites differing between disease
and healthy controls was visualized using the online tool Venny
[12].
2.6. Metabolite identiﬁcation
Accurate mass measurements were subjected to database
searches in the public databases METLIN [13] and Human Metab-
olome Database [14] as well as an in-house library comprising 384
synthetic standards. Database hits were then conﬁrmed by reten-
tion time match (in-house library only) and MS/MS spectral match
from the QC-samples. When data dependent MS/MS spectra were
missing, samples were re-analyzed using targeted MS/MS. In a few
cases, samples were also fractionated by LC and relevant fractions
were then analyzed by direct infusion on a Thermo Scientiﬁc
Orbitrap MS instrument to acquire MSn structural information. In
the case of multiple possible database hits, e.g. for structural iso-
mers, metabolites were annotated with compound class only.
Phospholipid species such as phosphatidylcholine (PC) and
lysophosphatidylcholines (LPC) were annotated using the formula
X:Y, where X ¼ number of carbon atoms and Y ¼ number of double
bonds. A phospholipid “O” annotation (e.g. LPC(O-X:Y)) represents
an alkyl ether bond; a “P” annotation (e.g. LPC(P-X:Y)) represents
an alkenyl ether bond. The sufﬁx “ox.” denotes oxidation.
3. Results
3.1. Quality control
The analytical repeatability of each of the selected metabolite
features was calculated as8.6% based on the QC-samples, which is
considered an acceptable coefﬁcient of variation according to FDA
guidelines [15]. Carry over was below the limit of detection as
determined by comparing the peak areas of lipophilic metabolites
(such as LPCs) in patient samples to blank sample injections. The
data were further visualized by principal components analysis and
box plot to verify sample homogeneity.
The clinical sample table (Table 1) shows disease and control
samples with equal gender ratios and matched age span. BMI was
signiﬁcantly different (Student's t-test p < 0.05) in the control
group compared to the three disease groups (control vs. heart
failure p ¼ 0.03; control vs. lymphoma p ¼ 0.03; control vs.
pneumonia p ¼ 0.01). Therefore BMI was considered a potential
confounding factor. Pearson correlation between BMI and all
selected metabolites respectively showed however no signiﬁcant
correlation (Supplementary Table 1).
3.2. 178 metabolites differed in disease compared to healthy
controls
Following MeOH extraction, serum samples were analyzed by
ultra-performance liquid chromatography-mass spectrometry
(UPLC-MS), detecting approximately 1200 metabolites per sample
(Fig. 1). After signal correction by sample-wise median intensity
normalization and frequency/abundance ﬁltering, 590 and 506
metabolites remained from the UPLC-MS positive and negative
mode analysis, respectively. Of these, 354 metabolites signiﬁcantly
differed in disease compared to healthy controls in positive mode,
while the corresponding number for negative mode was 205,
determined by Student's t-test with Benjamini Hochberg multiple
testing correction FDR limit of 5%. Removal of low quality metabolic
features and features overlapping between ionization modesresulted in a total of 178 differential metabolites, 106 and 72 in
positive and negative mode, respectively. Differential metabolites
were subsequently analyzed for overlap between diseases
compared to healthy controls. 66% of the differential metabolites
were identiﬁed.
3.3. A majority of differential metabolites overlap in disease
The number of metabolites differing between disease and con-
trol was largest in pneumonia (n ¼ 134), while the corresponding
number was 91 in lymphoma and 109 in heart failure (Fig. 2).
Likewise, pneumonia was the disease with the largest number of
unique metabolites (n ¼ 51). Only 12 and 6 metabolites were
unique to heart failure and lymphoma, respectively. Examples of
unique metabolites are displayed in Supplementary Fig. 1.
61% of the differential metabolites overlapped between two or
all three diseases compared to healthy controls. 26% of metabolites
overlapped between all three diseases, and amajority of thesewere
down-regulated in comparison to controls. Metabolites unique to a
certain disease and those overlapping between only two diseases
were to a larger extent up-regulated or regulated in opposite di-
rections in different diseases (Fig. 2).
3.4. 43% of metabolites overlapping between all three diseases are
lysophosphatidylcholines (LPCs) which may be connected to
immune responses
Of the metabolites overlapping between all three diseases
(Supplementary Table 2), the dominating metabolite class was
LPCs, of which all were down-regulated in disease compared to
healthy controls. A literature search for associations of this
metabolite class with disease showed a strong association between
serum LPC levels and various diseases (Fig. 3).
3.5. Implications for the design of biomarker discovery studies
We used our dataset to conceptually investigate the impact of
study design on results interpretation. One form of biomarker
discovery study design is to compare the disease of interest with
healthy controls [1,16]. In the present dataset this was for example
illustrated by the comparison of lymphoma patients with healthy
control subjects. One example of a metabolite differing between
these two groups was LPC(18:3) (Fig. 4A). Another possible study
design is to compare progression states of a disease such as stages
of a cancer [17]. Observing the relative concentration of LPC(18:3)
from stage I to stage IV lymphoma, a signiﬁcant trend emerged
(Fig. 4B). When however congestive heart failure and pneumonia
were included as non-related disease controls in the study design,
it became apparent that LPC(18:3) was not a disease speciﬁcmarker
(Fig. 4C).
4. Discussion
A key aspect of a biomarker discovery study is to ﬁnd disease
speciﬁc markers. The results from the present study show that the
number of general disease markers in serum may be larger than
expected, making the discovery of truly unique markers more
challenging. Our study cohort comprised serum samples from three
diseases that had been selected to represent clearly separate dis-
ease categories: malignancy (non-Hodgkin lymphoma), intrinsic
organ failure (congestive heart failure) and infectious disease
(community acquired pneumonia). Considering that these diseases
have very different etiology and clinical presentation, they would
be expected to have a large fraction of unique serum metabolic
markers when compared to healthy controls. Based on our results
Fig. 1. Schematic representation of study design. Serum samples from the three unrelated diseases non-Hodgkin lymphoma (L), community acquired pneumonia (P) and
congestive heart failure (H) and healthy controls (C) were analyzed by UHPLC-MS in positive and negative mode. All three disease groups were each compared to the healthy control
group by Student's t-test with Benjamini Hochberg correction for multiple testing (FDR 5%). Selected metabolite features were examined and reintegrated in the raw data and
statistical signiﬁcance was veriﬁed by t-test. Metabolites were then identiﬁed and subject to overlap analysis to identify metabolites speciﬁc to or shared between different diseases.
Fig. 2. Overlap analysis of metabolites differing between disease and healthy controls. Metabolites were selected by t-test with multiple test correction (Benjamini Hochberg
FDR 5%) (H ¼ congestive heart failure vs. controls, L ¼ lymphoma vs. controls, P ¼ pneumonia vs. controls). Of a total of 178 metabolites, 61% (109) were shared between two or all
three diseases (sections HL, HP, LP and HLP in the Venn diagram). While 51 metabolites were speciﬁc to pneumonia, the corresponding numbers were only 6 and 12 for lymphoma
and congestive heart failure, respectively. Fold change (FC) calculation showed that with few exceptions, overlapping metabolites were regulated in the same direction, with a
majority being down-regulated in comparison to healthy controls. Bar indicates FC of the respective metabolite in the respective disease versus healthy controls.
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markers seems in fact to be surprisingly small.
The metabolites phenylalanine, LPC(O-18:0), androsterone sul-
fate and LPC(20:5) were found down-regulated and speciﬁc to
lymphoma, congestive heart failure and pneumonia, respectively
(Supplementary Fig. 1). However, all four of these metabolites have
also been found speciﬁc to other diseases in previous studies un-
related to the present one. For example, phenylalanine was found
down-regulated in serum from patients with Alzheimer's diseasecompared to healthy controls [18]. The plasma levels of the phos-
pholipid LPC(O-18:0) were lower in bacteremia patients than in
controls [19]. Androsterone sulfate was found down-regulated in
plasma from patients with lung adenocarcinoma [20] and plasma
levels of LPC(20:5) were lower in women diagnosed with Gesta-
tional Diabetes Mellitus (GDM) [21]. These examples show that
potential metabolite disease markers risk being repeatedly identi-
ﬁed across a wide range of non-related disease states, and hence
not disease speciﬁc.
Fig. 3. A connection between serum LPC levels and immune responses. A. A number of LPCs found overlapping in this study (Supplementary Table 2) were associated with a
wide range of disease states in the literature. This indicates that serum LPC levels are likely to be connected to secondary systemic responses rather than perturbations in a disease
speciﬁc pathway. The y-axis gives the number of literature reports where a speciﬁc LPC is reported to be associated with a speciﬁc disease. PubMed and ISI Web of Science were
queried using the following search phrases in combinations for the different LPCs: LPC(X:Y), biomarker, disease, lysophosphatidylcholine, cancer, Alzheimer, diabetes, infection,
cardiovascular and serum. Studies involving humans were retained. See Supplementary Table 3 for references. B. LPCs play a central role in initiating and maintaining an in-
ﬂammatory response. Upon activation of the immune system, LPCs are released from plasma membranes and act as potent inﬂammatory mediators. As such, serum LPC levels are
likely to change with a range of pathological conditions.
Fig. 4. Implications for biomarker discovery study design. A hypothetical biomarker study aiming to discover lymphoma speciﬁc markers serves to illustrate how marker
speciﬁcity may be increased. A. Comparing healthy controls (C) with lymphoma (L) samples, LPC(18:3) is an example of a signiﬁcant single marker. B. Likewise, LPC(18:3) levels
correlate with lymphoma stage. C. However, when the non-related disease controls congestive heart failure (H) and community acquired pneumonia (P) are included it becomes
clear that LPC(18:3) is not disease speciﬁc but rather a general disease marker.
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samples or progressive disease states, proteins and presumably
metabolites that are part of a general stress- or inﬂammatory
response will display altered levels [22,23]. In the present study,
LPCs were in majority among the overlapping metabolites identi-
ﬁed (Supplementary Table 2). A systematic literature search
revealed that the levels of these phospholipids have repeatedly
been found altered in a number of different pathological conditions
including cancer, infection and diabetes (Fig. 3A, Supplementary
Table 3). LPCs are released by the action of phospholipases A2
(PLA2s) on plasma membrane phosphatidylcholines resulting in an
LPC and a free fatty acid (Fig. 3B). The free fatty acid, if being
arachidonic acid, can be further metabolized into various prosta-
glandin-, thromboxane- and leukotriene metabolites which
participate in inﬂammatory responses. LPCs and the downstream
metabolite lysophosphatidic acid (LPA) are emerging as equallyimportant inﬂammatory mediators [24]. For example, LPCs are
potent attractors of monocytes [25] and activators of macrophages
[26]. As LPCs are being released from apoptotic tissue or immune
cells such as neutrophils attracted to the site of insult or inﬂam-
mation, they will in turn attract and activate phagocytic cells [27].
Thus, LPCs play a central role in initiating and maintaining the in-
ﬂammatory response creating a rationale for postulating that LPC
levels in serum will change with a plethora of pathological condi-
tions that trigger inﬂammatory responses.
Further, activation and expansion of white blood cells such as
neutrophils and macrophages require substantial changes of their
intrinsic metabolism to sustain their immune functions. These
changes include increased glycolysis, glutaminolysis and fatty acid
oxidation [28]. At a certain critical level and magnitude of immune
cell activation, it is reasonable to assume that this altered metabolic
activity can leave a trace detectable in the blood, and that this trace
A. Lindahl et al. / Biochemical and Biophysical Research Communications 478 (2016) 1472e1477 1477will be speciﬁc to the immune cell status rather than to the cause of
the inﬂammation (Fig. 3B). When healthy control subjects were
compared to the entire lymphoma cohort in this study, LPC(18:3)
was one promising biomarker (Fig. 4A). Comparing the serum level
of LPC(18:3) in patients with different stages of lymphoma, pro-
gressive reduction of this metabolite appears to correlate with
disease stage I to IV (Fig. 4B). However, when the level of LPC(18:3)
in patients diagnosed with non-related diseases is included as well,
it becomes clear that this particular metabolite marker most likely
is indicative of disease in general rather than lymphoma speciﬁcally
(Fig. 4C). Based on our results, non-related disease controls would
help avoiding general disease markers and thus improve clinical
usefulness.
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